AR054815A1 - Compuestos que exhiben una actividad moduladora en el receptor 5-hidroxi-triptamina 6 - Google Patents
Compuestos que exhiben una actividad moduladora en el receptor 5-hidroxi-triptamina 6Info
- Publication number
- AR054815A1 AR054815A1 ARP060102858A ARP060102858A AR054815A1 AR 054815 A1 AR054815 A1 AR 054815A1 AR P060102858 A ARP060102858 A AR P060102858A AR P060102858 A ARP060102858 A AR P060102858A AR 054815 A1 AR054815 A1 AR 054815A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- hydrogen
- halogen
- cor9
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 150000002431 hydrogen Chemical group 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- 101100477978 Hypocrea jecorina (strain QM6a) sor6 gene Proteins 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- -1 N (R8) SO2R9 Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos que exhiben una actividad moduladora en el receptor 5-hidroxi triptonina 6 o sus sales, solvatos o sales solvatadas, procesos para su preparacion y a nuevos intermediarios utilizados en la preparacion de los mismos, composiciones farmacéuticas que contienen dichos compuestos y al uso de dichos compuestos en terapia. Reivindicacion 1: Un compuesto que tiene la formula 1 donde: Q es arilC6-10aIquiloC0-5, heteroarilC5-11alquiloC0-6, cicloaIquilC3-7alquiloC0-6, heterocicloalquiloC3-7 o alquiloC1-3; R1 es hidrogeno, hidroxilo, halogeno, alquiIoC1-6, aIqueniloC2-6, alquiniloC2-6, alcoxiC1-6, N(R8)2, arilC6-10alquiIoC0-3, heteroarilC5-6alquiloC0-3, haloalquiloC1-6, haloalquilC1-6O, R6OalquiloC0-6, CN, SR6, R6SO2alquiloC0-3, SOR6,. R6CON(R7)alquiloC0-3, NR7SO2R6, COR6, COOR6, OSO2R6, (R7)2NCOalquiIoC0-3, SO2N(R7)2, N(R7)CON(R7)2, NO2 u oxo; n es 0, 1, 2, 3 o 4; B es O, N(R5), o B es N en un heteroariloC5-11; X es O, CH2 o NR10; R2 es hidrogeno, hidroxilo, halogeno, alquiloC1-6, alcoxiC1-6, haloalquiloC1-6, haloalquiIC1-6O, R9OaIquiIoC0-6, CN, SR8, SO2R9, SOR9, N(R8)COR9, N(R8)SO2R9, COR9, COOR9, OSO2R9, CON(R8)2 o SO2N(R9)2; R3 es hidrogeno, alquiloC1-10, haloalquiloC1-6 o R9OalquiloC1-6; R4 es hidrogeno, alquiIoC1-5, haloalquiIoC1-5, aIcoxiC1-5 o haloalcoxiC1-5 y puede estar sustituido con uno o más grupos seleccionados independientemente entre halogeno, hidroxilo, ciano, alquiloC1-3 y alcoxiC1-3, o R3 y R4 forman entre si un heterocicloalquiloC3-7, el cual puede estar sustituido con uno o más grupos seleccionados independientemente entre hidrogeno, halogeno, alquiloC1-6, haloalquiloC1-6, COR9, SO2R9, OR9, ciano, oxo y SO2N(R8)2; R5 es hidrogeno, alquiloC1-6, R9OalquiloC1-6, haloalquiloC1-6 o cianoalquiloC1-6; R6 es alquiloC1-6, arilC6-10alquiloC0-3, heteroarilC5-6alquiloC0-3, cicloalquilC3-7alquiloC0-3 o haloalquiloC1-3; R7 es hidrogeno, alquiloC1-6, haloalquiloC1-6, cicloalquil C3-7alquiloC0-3 arilC6- 10alquiloC0-3, o heteroariIC5-6alquiloC0-3, o R6 y R7 forman entre si un heteroariloC5-6 o heterocicloalquiloC3-7, por lo cual cualquier arilo y heteroarilo bajo R1, R6 y R7 pueden ser sustituidos con uno o más grupos seleccionados independientemente entre hidrogeno, halogeno, hidroxilo, haloalquiloC1-6, CN, OR8, alquiloC1-6, oxo, SR8, CON(R8)2, N(R8)COR9, SO2R9, SOR9, N(R8)2 y COR9; R8 es hidrogeno, alquiloC1-6, cianoalquiloC1-6 o haloalquiloC1-6, R9 es alquiloC1-6, cianoalquiloC1-6 o haloalquiloC1-6; R8 y R9 forman entre si un heterocicloaIquiloC3-7 el cual puede estar sustituido con uno o más grupos seleccionados independientemente entre hidrogeno, halogeno, hidroxilo, alquiloC1-3, alcoxiC1-3 y ciano; y R10 es H, alquiloC1-6, haloalquiloC1-6, COR11 o SO2R11, o sus sales, solvatos o sales solvatadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501580 | 2005-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054815A1 true AR054815A1 (es) | 2007-07-18 |
Family
ID=37604727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102858A AR054815A1 (es) | 2005-07-05 | 2006-07-03 | Compuestos que exhiben una actividad moduladora en el receptor 5-hidroxi-triptamina 6 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100173890A1 (es) |
| EP (1) | EP1902041A4 (es) |
| JP (1) | JP2009500406A (es) |
| CN (1) | CN101258136A (es) |
| AR (1) | AR054815A1 (es) |
| TW (1) | TW200720262A (es) |
| WO (1) | WO2007004960A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5497429B2 (ja) * | 2007-03-07 | 2014-05-21 | 武田薬品工業株式会社 | ベンゾオキサゼピン誘導体およびその用途 |
| DE102007043759A1 (de) | 2007-09-13 | 2008-09-11 | Basf Se | Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat |
| JP5361733B2 (ja) * | 2007-11-15 | 2013-12-04 | 武田薬品工業株式会社 | ピリドオキサゼピン誘導体およびその用途 |
| JP2012527474A (ja) * | 2009-05-22 | 2012-11-08 | エクセリクシス， インク． | 増殖性疾患に対するベンゾキサゼピンベースのｐｉ３ｋ／ｍｔ０ｒ阻害剤 |
| BE1019008A3 (nl) | 2009-11-20 | 2011-12-06 | Flooring Ind Ltd Sarl | Vloerpaneel. |
| NO3175985T3 (es) * | 2011-07-01 | 2018-04-28 | ||
| IL316468A (en) * | 2022-04-22 | 2024-12-01 | Teijin Pharma Ltd | The aftermath of oxazepine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA786230B (en) * | 1977-12-21 | 1979-10-31 | Smithkline Corp | 8 and/or 9 substituted 2-benzazepine compounds |
| JP2000186088A (ja) * | 1998-10-16 | 2000-07-04 | Takeda Chem Ind Ltd | 含窒素縮合複素環誘導体、その製造法および用途 |
| AU6123699A (en) * | 1998-10-16 | 2000-05-08 | Takeda Chemical Industries Ltd. | Nitrogenous fused heterocycle compounds, process for the preparation thereof andagents containing the same |
| GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| DE10053799A1 (de) * | 2000-10-30 | 2002-05-08 | Bayer Ag | Verwendung von Tetrahydroisochinolinsulfonamiden |
| DE60232173D1 (de) * | 2001-11-09 | 2009-06-10 | Biovitrum Ab Publ | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme |
| EP1456178A1 (en) * | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| JP2005522452A (ja) * | 2002-02-13 | 2005-07-28 | グラクソ グループ リミテッド | Ｃｎｓ疾患の治療のための、５−ｈｔ６受容体アフィニティーを有する７−アリールスルホンアミド−２，３，４，５−テトラヒドロ−１ｈ−ベンゾ’ジアゼピン誘導体 |
-
2006
- 2006-07-03 CN CNA2006800325276A patent/CN101258136A/zh active Pending
- 2006-07-03 US US11/993,378 patent/US20100173890A1/en not_active Abandoned
- 2006-07-03 WO PCT/SE2006/000828 patent/WO2007004960A1/en not_active Ceased
- 2006-07-03 EP EP06747985A patent/EP1902041A4/en not_active Withdrawn
- 2006-07-03 AR ARP060102858A patent/AR054815A1/es not_active Application Discontinuation
- 2006-07-03 JP JP2008520213A patent/JP2009500406A/ja active Pending
- 2006-07-05 TW TW095124507A patent/TW200720262A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101258136A (zh) | 2008-09-03 |
| EP1902041A1 (en) | 2008-03-26 |
| TW200720262A (en) | 2007-06-01 |
| JP2009500406A (ja) | 2009-01-08 |
| EP1902041A4 (en) | 2010-03-17 |
| US20100173890A1 (en) | 2010-07-08 |
| WO2007004960A1 (en) | 2007-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR103812A2 (es) | Derivados de piperidina antagonistas de nk1 | |
| AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR045979A1 (es) | Amidas heterociclicas | |
| CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
| AR044342A1 (es) | Derivados de bencimidazol | |
| ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| AR034792A1 (es) | Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica | |
| AR064355A1 (es) | Herbicidas derivados de isoxazol | |
| AR060267A1 (es) | Tiazolil- dihidro -ciclopentapirazoles | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| UY27522A1 (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
| AR055635A1 (es) | Uso de sulfonanilidas como herbicidas | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR037676A1 (es) | Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion; composicion farmaceutica que los comprende y procedimiento para preparar compuestos de formula (i) | |
| CO5550398A2 (es) | 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos | |
| AR053994A1 (es) | Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| AR015528A1 (es) | Compuestos heterociclicos como inhibidores de enzimas rotamasas, composiciones, su uso para la preparacion de medicinas, proceso para su preparacion ycompuestos intermediarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |